by GlobeNewsWire | Sep 9, 2016 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (Nasdaq:CYTK) announced today that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial...
by GlobeNewsWire | Sep 9, 2016 | Globe Newswire
CAMBRIDGE, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) — CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, today announced the pricing of an...
by GlobeNewsWire | Sep 9, 2016 | Globe Newswire
CAMBRIDGE, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) — Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today...
by GlobeNewsWire | Sep 8, 2016 | Globe Newswire
CAMBRIDGE, Mass., Sept. 08, 2016 (GLOBE NEWSWIRE) — CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, today announced that it intends to...
by GlobeNewsWire | Sep 8, 2016 | Globe Newswire
–SUNRISE Top-line Data Accepted for Late-Breaking Oral Presentation at European Society of Medical Oncology Congress in October 2016 — — Avid First Quarter Revenue of $5.6 Million with Over $20 Million in Revenue Projected in Second Quarter —...